(Q34582779)

3 August 2017

title

Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules (English)

1 reference

3 August 2017

Hans C Ebbers

1

1 reference

3 August 2017

Esraa Al-Temimi

2

1 reference

3 August 2017

Ellen H M Moors

3

1 reference

3 August 2017

Aukje K Mantel-Teeuwisse

4

1 reference

3 August 2017

Huub Schellekens

5

1 reference

3 August 2017

Hubert G M Leufkens

6

1 reference

3 August 2017

language of work or name

1 reference

1 April 2013

1 reference

3 August 2017

1 reference

3 August 2017

volume

27

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

167-174

1 reference

Mechanisms of adverse drug reactions to biologics

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Early development of therapeutic biologics--pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Pharmacovigilance of biopharmaceuticals: challenges remain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Timing of new black box warnings and withdrawals for prescription medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

An update on the first decade of the European centralized procedure: how many innovative drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Predictors of infection in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Immunosuppressive drugs and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Clarification of terminology in drug safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

Adverse side-effects to biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

European biologicals registers: methodology, selected results and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0012-Y

10.1007/S40259-013-0012-Y

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference